Defects or damage in the genome due to genetic mutations lead to disease initiation through errors in cellular or tissue functions.
Gene therapy involves introducing genetic material responsible for the disease into the human body, restoring normal protein levels through protein replacement, and thereby recovering the functions of damaged cells and tissues.
This can address the fundamental cause of the disease.
Degenerative arthritis is increasing due to changes in lifestyle habits such as the growing elderly population, obesity, and lack of exercise.
Currently, for early stages of degenerative arthritis, pain relievers are prescribed, and for advanced stages, surgical treatments are performed. However, there is a lack of a therapeutic drug (Disease-Modifying Osteo Arthritis Drug, DMOAD) addressing the fundamental cause.
At Renhaim Inc., research is being conducted to develop a fundamental cause treatment (DMOAD) for the condition by inducing protein replacement within cartilage tissue using mRNA.
